Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTK6/BRK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTK6 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for kinase assays and binding affinity studies. |
View PTK6 Products |
| Gene Delivery | PTK6 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic assays. |
View PTK6 Products |
| Benchmark Ab | Anti-PTK6 Recombinant Antibody High-specificity recombinant positive control for Western Blot, IP, and IHC validation. |
View PTK6 Products |
| Validator | PTK6 siRNA Set Target-specific knockdown verification to rule out off-target small molecule toxicity. |
View PTK6 Products |
| Related Target A | EGFR Synergistic pathway partner; PTK6 physically associates with and sensitizes EGFR signaling in breast cancer. |
View EGFR Products |
| Related Target B | HER2 Co-expressed with PTK6 in breast tumors; PTK6 modulates HER2-induced cell migration and resistance. |
View HER2 Products |
| Related Target C | Src Highly homologous non-receptor tyrosine kinase; critical for off-target selectivity screening panels. |
View Src Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity Screening | Highly homologous kinase panel proteins (Src, Frk, Fyn) available with sequence verification and high purity (>95%). |
| Scaffolding vs. Catalytic Differentiation | Kinase-active WT and kinase-dead mutant PTK6 recombinant proteins for comparative binding assays (e.g., for PROTAC development). |
| Lack of Validated Positive Controls | Sequence-derived recombinant benchmark antibodies included for assay standardization. |
| Off-Target Phenotypic False Positives | Sequence-verified siRNA knockdown sets included for target-specific functional validation. |
Live PTK6/BRK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTK6 (Breast Tumor Kinase, BRK) therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective small molecules and targeted protein degradation (PROTACs). As first-generation broad-spectrum tyrosine kinase inhibitors face limitations due to off-target toxicities (principally from Src-family kinase inhibition), the next wave of R&D is targeting PTK6-specific structural pockets and its non-catalytic scaffolding functions in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecules | Academic Consortia, Biotech Startups | TNBC, Prostate Cancer, Colorectal Cancer | Kinase selectivity assays (Need high-purity PTK6 vs. Src family proteins) |
| PROTACs (Degraders) | Arvinas, University Lead Labs | Ovarian Cancer, Metastatic Breast Cancer | Ternary complex characterization (Need high-purity WT/Mutant PTK6) |
| Combination Therapies | Clinical Trial Sponsors | HER2+ Breast Cancer (TKI-resistant) | Synergistic pathway cell lines (Need PTK6 stable expression lentivirus) |